ADC Therapeutics SA (ADCT) 宣布 ZYNLONTA 的 LOTIS-7 试验更新。 ADC Therapeutics SA (ADCT) Announces Updates on LOTIS-7 Trial of ZYNLONTA.

ADC Therapeutics 在 LOTIS-7 1b 期试验中完成剂量递增，在复发/难治性 B 细胞非霍奇金淋巴瘤患者中测试非霍奇金淋巴瘤药物 ZYNLONTA® 与双特异性抗体 glofitamab 或 mosunetuzumab。 ADC Therapeutics completes dose escalation in LOTIS-7 Phase 1b trial, testing non-Hodgkin lymphoma drug ZYNLONTA® with bispecific antibodies glofitamab or mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma patients. 未发现剂量限制性毒性、低细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。 No dose-limiting toxicities, low cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome found. 剂量扩展阶段招募开始。 Dose expansion phase enrollment begins.